Oramed Pharmaceuticals has enroled and randomised more than 50% of participants in its second Phase III ORA-D-013-2 international multicentre trial of ORMD-0801, an oral insulin capsule, to treat type 2 diabetes (T2D).

About 450 T2D patients with insufficient glycemic control, handling their condition with diet alone or with diet along with metformin monotherapy are being recruited in the ORA-D-013-2 double-blind trial.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company’s proprietary lead candidate, ORMD-0801 is being assessed in two pivotal Phase III trials, ORA-D-013-1 and ORA-D-013-2, and can become the first treatment for diabetes by orally delivering insulin at an early stage.

The Phase III ORA-D-013-1 trial completed subject enrolment in May this year and expects to receive top line findings in January next year.

Oramed CEO Nadav Kidron said: “We are very pleased as we head into the latter half of enrolment for our ORA-D-013-2 trial, especially after having just completed 100% enrolment in our larger ORA-013-1 trial which randomised a total of 710 patients.

“Together, these trials are the world’s first Phase 3 oral insulin trials conducted under a US FDA IND.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The ORA-D-013-2 trial is being conducted under the US Food and Drug Administration (FDA) Investigational New Drug Application (IND).

In this trial, the subjects will be randomised in 1:1 two cohorts and administered with 8mg ORMD-0801 or placebo at night.

The efficacy of ORMD-0801 compared to placebo in enhancing glycemic control as evaluated by A1c over a treatment period of 26 weeks will be the trial’s primary endpoint.

Comparing the ORMD-0801 vs placebo in maintaining the glycemic control for 52-week treatment period will be the secondary endpoint of the trial.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact